Oncopeptides AB - Asset Resilience Ratio

Latest as of December 2023: 0.01%

Oncopeptides AB (ONCO) has an Asset Resilience Ratio of 0.01% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ONCO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr32.00K

≈ $3.44K USD Cash + Short-term Investments

Total Assets

Skr238.38 Million

≈ $25.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Oncopeptides AB's Asset Resilience Ratio has changed over time. See Oncopeptides AB net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Oncopeptides AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ONCO market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr32.00K	0.01%
Total Liquid Assets	Skr32.00K	0.01%

Asset Resilience Insights

Limited Liquidity: Oncopeptides AB maintains only 0.01% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Oncopeptides AB Industry Peers by Asset Resilience Ratio

Compare Oncopeptides AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Oncopeptides AB (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Oncopeptides AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.01%	Skr32.00K ≈ $3.44K	Skr238.38 Million ≈ $25.65 Million	-0.08pp
2022-12-31	0.09%	Skr348.00K ≈ $37.45K	Skr385.32 Million ≈ $41.47 Million	-0.39pp
2021-12-31	0.48%	Skr2.11 Million ≈ $227.28K	Skr439.38 Million ≈ $47.28 Million	-0.81pp
2020-12-31	1.29%	Skr12.23 Million ≈ $1.32 Million	Skr946.76 Million ≈ $101.89 Million	+1.48pp
2018-12-31	-0.19%	Skr-850.00K ≈ $-91.47K	Skr444.53 Million ≈ $47.84 Million	-0.14pp
2017-12-31	-0.05%	Skr-262.00K ≈ $-28.20K	Skr479.82 Million ≈ $51.64 Million	+0.42pp
2016-12-31	-0.47%	Skr-261.89K ≈ $-28.18K	Skr55.63 Million ≈ $5.99 Million	--

pp = percentage points

About Oncopeptides AB

ST:ONCO Sweden Biotechnology

Market Cap

$67.06 Million

Skr623.18 Million SEK

Market Cap Rank

#20852 Global

#374 in Sweden

Share Price

Skr1.64

Change (1 day)

+1.81%

52-Week Range

Skr1.27 - Skr6.31

All Time High

Skr343.59